0001387131-22-010256.txt : 20221004 0001387131-22-010256.hdr.sgml : 20221004 20221004060149 ACCESSION NUMBER: 0001387131-22-010256 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20221003 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221004 DATE AS OF CHANGE: 20221004 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adamis Pharmaceuticals Corp CENTRAL INDEX KEY: 0000887247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820429727 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36242 FILM NUMBER: 221289652 BUSINESS ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 997-2400 MAIL ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: CELLEGY PHARMACEUTICALS INC DATE OF NAME CHANGE: 19950615 8-K 1 admp-8k_100322.htm CURRENT REPORT
0000887247 false 0000887247 2022-10-03 2022-10-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 3, 2022

 

ADAMIS PHARMACEUTICALS CORPORATION

(Exact Name of Registrant as Specified in Charter)

 

Delaware   0-26372   82-0429727
(State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)

 

11682 El Camino Real, Suite 300

San Diego, CA

   92130
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (858) 997-2400

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

  Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   ADMP   NASDAQ Capital Market

 

 

 

 

 

 

  Item 8.01 Other Events

On October 3, 2022, Adamis Pharmaceuticals Corporation (the “Company”) issued a press release announcing that following the recently announced halting of the Company’s Phase 2/3 clinical trial examining the effects of Tempol in high risk subjects with early COVID-19 infection, it has initiated a process to explore a range of strategic and financing alternatives focused on maximizing stockholder value. Potential alternatives that may be explored or evaluated include a partnership regarding or sale of one or both of the Company’s commercial products SYMJEPI® and ZIMHI®, a merger, sale, or reverse merger of the Company, and/or seeking additional financing. As part of this process, the Company has engaged the investment bank Raymond James & Associates, Inc. to act as strategic advisor to assist the Company in evaluating certain alternatives. There can be no assurance regarding the schedule for completion of the strategic review process, that this strategic review process will result in the Company pursuing any transaction or that any transaction, if pursued, will be completed. The Company is also reviewing and intends to pursue expense reduction alternatives and measures which may include, without limitation, employee headcount reductions and reduction or discontinuation of certain product development programs.

A copy of the Company’s press release is filed with this Report as Exhibit 99.1, and is incorporated herein by reference. 

Forward Looking Statements

This Current Report on Form 8-K, and the press release filed as an exhibit with this Report, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that express plans, anticipation, intent, contingencies, goals, targets or future development and/or otherwise are not statements of historical fact. These statements relate to future events or future results of operations, including, but not limited to statements concerning the following matters: the Company’s review and evaluation of potential strategic alternatives and their impact on stockholder value; the process by which the Company engages in evaluation of strategic alternatives; the Company’s ability to identify potential buyers or partners for one or both the Company’s commercial products; the Company’s ability to identify potential merger or acquisition partners; the Company’s ability to raise capital to continue as a going concern; the possibility that the Company may be required to seek bankruptcy protection or other alternatives for restructuring and resolving its liabilities; the terms, timing, structure, benefits and costs of any strategic transaction and whether one will be consummated at all; and the impact of any strategic transaction on the Company. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, which may cause Adamis’ actual results to be materially different from the results anticipated by such forward-looking statements. Factors that could cause actual results to differ materially from management’s current expectations include those risks and uncertainties relating to: our ability to raise capital; the results of our strategic review process; our revenues, cash flow, cash burn, expenses, obligations and liabilities, and ability to pay expenses and satisfy obligations as they become due; the interest of third parties in entering into a merger, reverse merger, or other strategic transaction with the Company or in purchasing or entering into a partnership regarding one or more of our commercial products; any impact of this evaluation process on the sale of the Company’s commercial products; the outcomes of any litigation, regulatory proceedings, inquiries or investigations that we are or may become subject to; the timing and results of our efforts to sell assets relating to our former compounding pharmacy business; and other important factors discussed in the Company’s filings with the Securities and Exchange Commission (“SEC”). In addition, forward-looking statements concerning our anticipated future activities assume that we have sufficient funding to support such activities and continue our operations and planned activities, which may not be the case. If we are unable to timely complete a transaction or we do not obtain required additional equity or debt funding or obtain required funding from other sources or transactions, our cash resources will be depleted and we could be required to materially reduce or suspend operations, which would likely have a material adverse effect on our business, stock price and our relationships with third parties with whom we have business relationships. If we do not have sufficient funds to continue operations or satisfy our liabilities, we could be required to seek bankruptcy protection or other alternatives to attempt to resolve our obligations and liabilities, which could result in our stockholders losing some or all of their investment in us. You should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as may be required by applicable law, we undertake no obligation to update or release publicly the results of any revisions to these forward-looking statements or to reflect events or circumstances arising after the date of this press release. Certain of these risks and additional risks, uncertainties, and other factors are described in greater detail in Adamis’ filings from time to time with the SEC, including its annual report on Form 10-K for the year ended December 31, 2021, and subsequent filings with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC’s website at http://www.sec.gov. 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

  99.1 Press release dated October 3, 2022.

 

 

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  ADAMIS PHARMACEUTICALS CORPORATION
   
   
Dated: October 3, 2022 By: /s/ David C. Benedicto
  Name: David C. Benedicto
  Title: Chief Financial Officer

 

 

 

 EX-99.1 2 ex99-1.htm PRESS RELEASE
 

Adamis Pharmaceuticals Corporation 8-K

 

Exhibit 99.1

 

Adamis Announces Review of Strategic Alternatives

 

 

SAN DIEGO, October 3, 2022-- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, announced today that following the recently announced halting of the Company’s Phase 2/3 clinical trial examining the effects of Tempol in high risk subjects with early COVID-19 infection, it has initiated a process to explore a range of strategic and financing alternatives focused on maximizing stockholder value. Potential alternatives that may be explored or evaluated include a partnership or sale of one or both of the Company’s commercial products SYMJEPI® and ZIMHI®, a merger, sale, or reverse merger of the Company, and/or seeking additional financing.

 

As part of this process, the Company has engaged the investment bank Raymond James & Associates, Inc. to act as strategic advisor to assist the Company in evaluating certain alternatives. There can be no assurance that this strategic review process will result in the Company pursuing any transaction or that any transaction, if pursued, will be completed. The Company has not established a schedule for completion of this strategic review process, nor has it made any definitive decisions at this time related to strategic alternative transactions. If the Company is unable to complete a transaction, it may be required to seek bankruptcy protection or other alternatives for restructuring and resolving its liabilities. The Company does not expect to disclose or provide an update concerning developments related to this process until the Company enters in definitive agreements or arrangements with respect to a transaction or otherwise determines that other disclosure is necessary or appropriate. The Company is also reviewing and intends to pursue expense reduction alternatives and measures which may include, without limitation, employee headcount reductions and reduction or discontinuation of certain product development programs.

 

About Adamis Pharmaceuticals

 

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The Company’s SYMJEPI® (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The Company’s ZIMHI® (naloxone) Injection product is approved for the treatment of opioid overdose. Tempol, in development for the treatment of patients with COVID-19, was the subject of a Phase 2/3 clinical trial which has been halted. For additional information about Adamis Pharmaceuticals, please visit our website and follow us on Twitter and LinkedIn.

 

 
 

Forward Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that express plans, anticipation, intent, contingencies, goals, targets or future development and/or otherwise are not statements of historical fact. These statements relate to future events or future results of operations, including, but not limited to statements concerning the following matters: the Company’s review and evaluation of potential strategic alternatives and their impact on stockholder value; the process by which the Company engages in evaluation of strategic alternatives; the Company’s ability to raise capital; the Company’s ability to identify potential buyers or partners for one or both the Company’s commercial products; the Company’s ability to identify potential merger or acquisition partners; the Company’s ability to raise capital to continue as a going concern; and the terms, timing, structure, benefits and costs of any strategic transaction and whether one will be consummated at all; the impact of any strategic transaction on the Company. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, which may cause Adamis’ actual results to be materially different from the results anticipated by such forward-looking statements. Factors that could cause actual results to differ materially from management’s current expectations include those risks and uncertainties relating to: our ability to raise capital; the results of our strategic review process; our cash flow, cash burn, expenses, obligations and liabilities; the interest of third parties in entering into a merger, reverse merger, or other strategic transaction with the Company or in purchasing one or more of our commercial products; any impact of this evaluation process on the sale of the Company’s commercial products; the outcomes of any litigation, regulatory proceedings, inquiries or investigations that we are or may become subject to; and other important factors discussed in the Company’s filings with the Securities and Exchange Commission (“SEC”). If we do not obtain required additional equity or debt funding, our cash resources will be depleted and we could be required to materially reduce or suspend operations, which would likely have a material adverse effect on our business, stock price and our relationships with third parties with whom we have business relationships, at least until additional funding is obtained. If we do not have sufficient funds to continue operations or satisfy out liabilities, we could be required to seek bankruptcy protection or other alternatives to attempt to resolve our obligations and liabilities that could result in our stockholders losing some or all of their investment in us. You should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as may be required by applicable law, we undertake no obligation to update or release publicly the results of any revisions to these forward-looking statements or to reflect events or circumstances arising after the date of this press release. Certain of these risks and additional risks, uncertainties, and other factors are described in greater detail in Adamis’ filings from time to time with the SEC, including its annual report on Form 10-K for the year ended December 31, 2021, and subsequent filings with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC’s website at http://www.sec.gov.

 

Contacts

 

Adamis Investor Relations

Robert Uhl

Managing Director

ICR Westwicke

619.228.5886

robert.uhl@westwicke.com

 

 

 

 EX-101.SCH 3 admp-20221003.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 admp-20221003_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 admp-20221003_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Oct. 03, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 03, 2022
Entity File Number 0-26372
Entity Registrant Name ADAMIS PHARMACEUTICALS CORPORATION
Entity Central Index Key 0000887247
Entity Tax Identification Number 82-0429727
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 11682 El Camino Real
Entity Address, Address Line Two Suite 300
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code (858)
Local Phone Number 997-2400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ADMP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 admp-8k_100322_htm.xml IDEA: XBRL DOCUMENT 0000887247 2022-10-03 2022-10-03 iso4217:USD shares iso4217:USD shares 0000887247 false 8-K 2022-10-03 ADAMIS PHARMACEUTICALS CORPORATION DE 0-26372 82-0429727 11682 El Camino Real Suite 300 San Diego CA 92130 (858) 997-2400 false false false false false Common Stock ADMP NASDAQ EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( #@P1%4'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " X,$1560HQ>.X K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)^D6#Z';B^))07!!\1:2V=U@\X=DI-VWMXV[740?P&-F?OGF M&YA.1ZE#PN<4(B:RF&\F-_@L==RR(U&4 %D?T:E\?$S#05F-." #CUE$+4 UB\3 MXVD:.K@"%AAA7\JZE?69 ME-621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M #@P1%7Y9O])6@0 !(1 8 >&PO=V]R:W-H965T&UL MC9AO5:[SL68K/59H<]&F1LPP.N?V1S!2.[5(E$PM-6S&4RCH>48(A[S4!L)!C\OW.=Q;)2 XY^CJ%5>TP2> M;K^KWQS8CGW9?Q31'H[M'H6B?B:[6*]D/MO_'A#!6 HX[SX)OO#N>VV M1<)=KF5R# :"1*2'7_9Z3,1)0.OF3 ]!M""^W"A@G+,-!L-E-P39P^X.8?1,V"S4U\1I?2'4H?2_ MX380E!BTQ*"%7@O#(']YJUPK*-3?=40'A7:]@NG>VSQC(1]:T)XY5R_<&OWZ MB]MQ?D/X6B5?"U,?C66X@U[49/F6\3HX/+QW]1V!:)<0;53% X*HH+B/V::. M H]?LSCG",=-R7%S63+F7 D9D4D:$6B^VKS@2D4;%7W4U$B=DJV#*DY2+?0; MN1KC"09Y8O/N)9!>%($YYE_> M-\@#G$=F:3T9+NFZG1XEDYCX#"8F"5W.8HRUF@MUK+BDL%.0#5: MCH,!5I.!B]OY1T#?C*#42[E/:^%PN8"E9"SX1F)PU23AXB[_$:YLQ+F2+R(- MZTN-:_H>AE;-&RYN]Q_1YC+7X#1_BNS\TX$K]JG;0FM:S1LN;OI%#3U8V)Y' MP04^]6YZGS&4:M)P<;=_D"%D9;Z5*3:'-8CT^]TKVL8;OIH97-S0?RJA-4\A M-4FR2X_^F]=2X4)-2Q"WFA5?(@ZLT\=!J%J"X M3\\5OPHA/1R>L,-*$19KL*:=K=?U]6O0:R2KK)_B/OT_LFF>[X"L$1"7;00\ M6?OCYKP4&E9KGN#4O%8M, MBP5OR4K6-EB#@#=^G&,DE:U3W(+?LT(FK^&6I1M^=BG9(/3D!6/O=XRI\G-Z MD9]/$JXV)DM?04%OC4MD+*VO'RYXMJ?LDS=<\V_!(S-7S$G,UR#D7'=!5QU> MP \#+;/BI76QEO%DN7/ZZZ>S;"=I=67=A['-HN6/O.-%Q[I#)6,>=56R=M8SDK6W!2 M,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B M6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG- M@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3T MXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(? M]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I M^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE< MA!OZ%>Y7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=> MBD[E\ZI[J,NXZBQ_AOMHD\%G'!QR>(W?#$T

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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://adamispharmaceuticals.com/role/Cover Cover Cover 1 false false All Reports Book All Reports admp-8k_100322.htm admp-20221003.xsd admp-20221003_lab.xml admp-20221003_pre.xml ex99-1.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "admp-8k_100322.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "admp-8k_100322.htm" ] }, "labelLink": { "local": [ "admp-20221003_lab.xml" ] }, "presentationLink": { "local": [ "admp-20221003_pre.xml" ] }, "schema": { "local": [ "admp-20221003.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ADMP", "nsuri": "http://adamispharmaceuticals.com/20221003", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "admp-8k_100322.htm", "contextRef": "From2022-10-03to2022-10-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://adamispharmaceuticals.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "admp-8k_100322.htm", "contextRef": "From2022-10-03to2022-10-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001387131-22-010256-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001387131-22-010256-xbrl.zip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